Post-marketing safety signals, therapeutic failure, and product-use issues reported with injectable Cabenuva: A FAERS disproportionality analysis
{{output}}
Background: Cabenuva (cabotegravir/rilpivirine) is the first complete long-acting injectable regimen for HIV-1 treatment. As its use expands, post-marketing surveillance should address not only conventional adverse reactions, but... ...
